Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors
Maria Vieito, Elisa Fontana, Catherine H Han, Eduardo Castanon, David J Pinato, Oliver Bechter, Rikke L Eefsen, Irene Moreno, Hans Prenen, Reinhard Dummer, Ruth Plummer, Gabriel Schnetzler, Martin Kornacker, Piergiorgio Pettazzoni, Florian Renner, Mahdi About, Martha L Serrano-Serrano, Christina Godfried Sie, Abiraj Keelara, Andreas RollerDavid Dejardin, Elisa Cinato, Tomi Fakolade, Ernesto Guarin, Nick Flinn, Nicole A Kratochwil, Nino Keshelava
Dyk ned i forskningsemnerne om 'Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors'. Sammen danner de et unikt fingeraftryk.
Keyphrases
Pharmacology, Toxicology and Pharmaceutical Science